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ORIGINAL RESEARCH ARTICLE
BACKGROUND: Increased risks of cardiac morbidity and mortality among 
childhood cancer survivors have been described previously. However, 
little is known about the very long-term risks of cardiac mortality and 
whether the risk has decreased among those more recently diagnosed. We 
investigated the risk of long-term cardiac mortality among survivors within 
the recently extended British Childhood Cancer Survivor Study.
METHODS: The British Childhood Cancer Survivor Study is a population-
based cohort of 34 489 five-year survivors of childhood cancer diagnosed 
from 1940 to 2006 and followed up until February 28, 2014, and is the 
largest cohort to date to assess late cardiac mortality. Standardized 
mortality ratios and absolute excess risks were used to quantify cardiac 
mortality excess risk. Multivariable Poisson regression models were used 
to evaluate the simultaneous effect of risk factors. Likelihood ratio tests 
were used to test for heterogeneity and trends.
RESULTS: Overall, 181 cardiac deaths were observed, which was 3.4 
times that expected. Survivors were 2.5 times and 5.9 times more at 
risk of ischemic heart disease and cardiomyopathy/heart failure death, 
respectively, than expected. Among those >60 years of age, subsequent 
primary neoplasms, cardiac disease, and other circulatory conditions 
accounted for 31%, 22%, and 15% of all excess deaths, respectively, 
providing clear focus for preventive interventions. The risk of both overall 
cardiac and cardiomyopathy/heart failure mortality was greatest among 
those diagnosed from 1980 to 1989. Specifically, for cardiomyopathy/
heart failure deaths, survivors diagnosed from 1980 to 1989 had 28.9 
times the excess number of deaths observed for survivors diagnosed 
either before 1970 or from 1990 on.
CONCLUSIONS: Excess cardiac mortality among 5-year survivors of 
childhood cancer remains increased beyond 50 years of age and has clear 
messages in terms of prevention strategies. However, the fact that the 
risk was greatest in those diagnosed from 1980 to 1989 suggests that 
initiatives to reduce cardiotoxicity among those treated more recently may 
be having a measurable impact.
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Treatment for childhood cancer has changed sub-stantially over the past 50 years. In particular, since 1990, there have been attempts to reduce 
treatment intensity among children with relatively good-
prognosis neoplasms with the aim of reducing the risk 
of treatment-related morbidity and mortality. Previous re-
search has identified that thoracic radiotherapy and spe-
cific types of chemotherapy, particularly anthracyclines, 
which were introduced in the late 1970s, increase the 
risk of cardiac disease among survivors of childhood 
cancer.1,2 Thus, it is important to assess whether there 
is evidence of a measurable decline in the risk of death 
from cardiac disease among those treated since 1990.
However, to date, only 2 studies have investigated 
the risk of cardiac mortality in relation to treatment era, 
both of which were restricted by narrow treatment era 
time spans.3,4 For this reason, we have investigated the 
risk of cardiac mortality among nearly 35 000 survivors 
of childhood cancer included in the BCCSS (British Child-
hood Cancer Survivor Study), the largest study to as-
sess mortality in survivors of childhood cancer.5 Princi-
pal advantages of the BCCSS compared with previous 
studies are that it is large-scale and population based 
and includes survivors treated across almost 7 decades 
(1940–2006), enabling an assessment of the risk of car-
diac mortality in relation to a wide span of treatment 
eras. Furthermore, because the BCCSS has an unrivaled 
number of survivors from earlier treatment decades, 
we have undertaken the most powerful investigation of 
excess cardiac mortality risks among childhood cancer 
survivors >50 years of age. As a result, the findings 
from this study provide new evidence with which to in-
form survivors of childhood cancer and clinicians and to 
update clinical follow-up guidelines.
METHODS
The BCCSS
The BCCSS comprises 34 489 five-year survivors of child-
hood cancer diagnosed under 15 years age from 1940 to 
2006 in Britain. The cohort was the first national population-
based study of survivors of childhood cancer to be untaken in 
Great Britain and was identified from the National Registry of 
Childhood Tumors, which has an ≈99% ascertainment rate.6 
The study is maintained at the Center for Childhood Cancer 
Survivor Studies, where research on a wide spectrum of pos-
sible adverse health outcomes of childhood cancer and its 
treatment is undertaken. Additional details relating to the study 
may be found online7 and in the descriptive article concerned 
with methodological aspects underlying the BCCSS.8 Ethics 
approval for the study was obtained from the National Research 
Ethics Service, and legal approval to process identifiable data 
without consent was approved by the Confidentiality Advisory 
Group. Descriptive characteristics of the BCCSS cohort can be 
found in Tables I–III in the online-only Data Supplement.
Death Ascertainment
Collaboration with the Health and Social Care Information 
Center (England and Wales) and National Health Service Central 
Register (Scotland) enabled us to ascertain each survivor’s vital 
and residency/emigration status. For each death, an attempt 
was made to obtain the death certificate and underlying cause 
of death as coded by the Office of National Statistics (England 
and Wales) and National Records of Scotland (Scotland) 
using the relevant International Classification of Diseases. 
International Classification of Diseases codes corresponding 
to a cardiac death were identified and subcategorized into clini-
cally relevant groups for analysis, specifically ischemic heart 
disease (IHD), cardiomyopathy/heart failure (CM/HF), arrhyth-
mias, pericardial disease, and valvular disease (Table IV in the 
online-only Data Supplement). Follow-up for cardiac mortality 
began at 5-year survival and continued until the first instance 
of emigration, death, or February 28, 2014.
Statistical Analyses
Standardized mortality ratios (SMRs) and absolute excess 
risks (AERs) were calculated with standard cohort techniques.9 
The SMR was defined as the observed divided by the expected 
number of deaths. The AER was defined as the observed minus 
the expected number of deaths divided by person-years at risk 
multiplied by 10 000. Expected numbers were calculated by 
multiplying the person-years within each sex-, age- (quinquen-
nial), and calendar year- (single year) specific stratum by the 
Clinical Perspective
What Is New?
• We report for the first time risks of cardiac mortality 
among 5-year survivors of childhood cancer beyond 
50 years of age.
• In particular, among those >60 years of age, sub-
sequent primary neoplasms, cardiac disease, and 
other circulatory conditions accounted for 31%, 
22%, and 15% of all excess deaths, respectively, 
providing clear focus for preventive interventions.
• The present study is also the first to show that the 
number of excess cardiac deaths, in particular car-
diomyopathy/heart failure deaths, was greatest 
among those diagnosed in the 1980s.
What Are the Clinical Implications?
• Our findings suggest that cardiac disease becomes 
increasingly important as childhood cancer survivors 
reach mature adulthood, suggesting that initiatives 
aimed at preventing excess mortality and morbidity 
in survivors >50 years of age should be focused 
on both subsequent primary neoplasm and cardiac 
disease prevention, surveillance, and management.
• Nonetheless, efforts to reduce cardiotoxicity among 
those treated more recently appear to be having a 
measurable impact because the number of excess 
cardiac deaths was greatest among survivors diag-
nosed in the 1980s.
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corresponding mortality rate for the population of England and 
Wales and then summing across the strata.10
Multivariable Poisson regression models for the SMRs and 
AERs were then fitted to evaluate the simultaneous effect of 
the following demographic- and cancer-related factors: sex, 
first primary neoplasm (FPN) type, age at cancer diagnosis, 
treatment era of diagnosis, and attained age. The results from 
the adjusted multivariable model were reported in terms of rela-
tive risks (which may be interpreted as the ratios of the SMRs 
adjusted for other factors fitted) and excess mortality ratios 
(EMRs; which may be interpreted as the ratios of the AERs 
adjusted for other factors fitted9; Table V in the online-only Data 
Supplement). To test for heterogeneity or linear trend, likelihood 
ratio tests within Poisson regression models were used. P for 
heterogeneity tests the null hypothesis that the relative risks or 
EMRs are equal across levels of the factor concerned, against 
the alternative hypothesis that the relative risks or EMRs vary 
across levels of the factor, having adjusted for other factors 
included within the model. P for trend tests the null hypothesis 
that the relative risks or EMRs are equal across levels of the fac-
tor concerned, against the alternative hypothesis that the rela-
tive risks or EMRs increase or decrease linearly across levels 
of the factor, having adjusted for other factors included within 
the model. Because we anticipated a priori that there might be 
evidence of risks increasing and then declining as treatment era 
became more recent, particularly in relation to anthracycline-
related CM/HF, we also investigated for evidence of a quadratic 
relationship in risks with treatment era using likelihood ratio 
tests within multivariable Poisson regression models. P for qua-
dratic tests whether there is evidence of such a specific type 
of systematic nonlinear variation in the relative risks or EMRs 
across levels of the factor concerned, having adjusted for other 
factors included within the model.
Cumulative mortality, as a function of follow-up, was esti-
mated by use of the stcompet command in Stata.11 Causes 
of death other than the one under study were treated as com-
peting risks.12,13 To test for heterogeneity among cumulative 
mortality curves, log-rank tests were used.
All analyses were completed with Stata 13.1,11 for which 
the criterion for statistical significance was a 2-sided value of 
P<0.05.
Patient Involvement
Overall, survivors showed their support for the study by return-
ing 10 488 BCCSS questionnaires, which represented 80% of 
those sent to survivors. Furthermore, almost all survivors com-
pleting the BCCSS questionnaire requested receipt of study 
newsletters, the means by which we inform survivors of the 
findings of the research. Last, 2 patient representatives attend 
the BCCSS Steering Group meetings and provide feedback on 
research priorities and research translation.
RESULTS
Study Characteristics
From 5-year survival, the cohort was followed up for a 
total of 620 753 person-years, with a mean follow-up of 
18.0 years (range, 0.0–68.7 years) and to a mean at-
tained age of 29.6 years (range, 5.5–85.6 years). By 
the study exit date, 4475 individuals (13.0%) in the co-
hort had died; of those deaths, 181 (4.0%) were attrib-
uted to cardiac causes (Table 1). The mean follow-up 
time from diagnosis and attained age at cardiac death 
were 31.4 and 39.2 years, respectively, which were 
greater than that observed for individuals who died of 
a noncardiac cause. Men accounted for approximately 
two thirds (63.5%) of the cardiac deaths, and survivors 
of central nervous system tumors (excluding primitive 
neuroectodermal tumor), Hodgkin lymphoma (HL), and 
Wilms accounted for nearly 50% of the cardiac deaths 
observed when combined.
Overall Cardiac Mortality
Survivors of childhood cancer experienced 3.4 times 
(95% confidence interval [CI], 2.9–3.9) the number of 
cardiac deaths expected from the general population, 
which equated to 2.1 (95% CI, 1.6–2.5) excess cardiac 
deaths per 10 000 person-years (Table 2). All FPN types 
with at least 5 observed cardiac deaths were at a statis-
tically significant increased risk of cardiac death (Table 3). 
The SMR was substantially raised (SMR>5.0) for survi-
vors of acute myeloid leukemia, Wilms, and HL at 23.5 
(95% CI, 11.2–43.1), 6.5 (95% CI, 4.0–10.0), and 5.4 
(95% CI, 3.7–7.6), respectively. From 5 to 19 to >60 
years of age, the SMR declined from 9.7-fold (95% CI, 
5.9–15.0) to 2.2-fold (95% CI, 1.3–3.5) that expected, 
respectively, whereas for the same age groupings the 
AER rose from 0.7 (95% CI, 0.4–1.1) to 23.7 (95% CI, 
3.6–43.8) excess cardiac deaths per 10 000 person-
years; both of these trends were statistically significant 
(SMR P for trend=0.0065; AER P for trend<0.0001). 
When assessed by treatment era, evidence of a qua-
dratic relationship was identified for the SMRs (P for 
quadratic=0.0014) and AERs (P for quadratic=0.0072), 
where after adjustment the risk was higher among those 
treated in the 1980s than those treated in decades be-
fore or since (Table 4). Compared with those diagnosed 
before 1970, the relative risk for cardiac death was 1.6 
times (95% CI, 1.1–2.5), 2.3 times (95% CI, 1.4–3.8), 
and 1.0 times (95% CI, 0.4–2.1) higher among those di-
agnosed in 1970 to 1979, 1980 to 1989, and 1990 to 
2006, respectively, after adjustment for sex, FPN type, 
age at diagnosis, and attained age.
In Table 5, we provide the percentage contributions 
of specific causes of death to the total excess number 
of deaths observed at different attained ages. Among 
those >60 years of age, cardiac deaths accounted for 
22% and 41% of all excess deaths and all excess non-
neoplastic deaths, respectively. Of all excess deaths ob-
served among those >60 years of age, 31%, 22%, and 
15% were attributable to subsequent primary neoplasms 
(SPNs), cardiac disease, and other circulatory diseases, 
respectively, accounting for 68% of the excess number 
of deaths overall.
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Table 1. Study Characteristics of the British Childhood Cancer Survivor Study
Patient Characteristic
Cardiac Deaths Other Deaths
P Value
Total
n % n % n %
Overall 181 100.0 4294 100.0 4475 100.0
  Sex
   Male 115 63.5 2524 58.8 2629 58.7
   Female 66 36.5 1780 41.5 0.182 1846 41.3
FPN type
  CNS (excluding PNET) 32 17.7 1302 30.3 1334 29.8
  CNS PNET 5 2.8 336 7.8 341 7.6
  Leukemia (excluding AML) 17 9.4 1086 25.3 1103 24.6
  AML 10 5.5 72 1.7 82 1.8
  HL 33 18.2 298 6.9 331 7.4
  NHL 17 9.4 114 2.7 131 2.9
  Neuroblastoma 4 2.2 140 3.3 144 3.2
  Nonheritable retinoblastoma 2 1.1 29 0.7 31 0.7
  Heritable retinoblastoma 4 2.2 134 3.1 138 3.1
  Wilms 20 11.0 164 3.8 184 4.1
  Bone sarcoma 9 5.0 189 4.4 198 4.4
  Soft tissue sarcoma 12 6.6 241 5.6 253 5.7
 Other 16 8.8 189 4.4 <0.001 205 4.6
Age at diagnosis, y
  Mean 7.8  7.3   7.3  
  0–4 63 34.8 1598 37.2  1661 37.1
  5–9 46 25.4 1306 30.4  1352 30.2
  10–14 72 39.8 1390 32.4 0.099 1462 32.7
Treatment era
  1940–1969 79 43.6 1250 29.1  1329 29.7
  1970–1979 48 26.5 1199 27.9  1247 27.9
  1980–1989 43 23.8 898 20.9  941 21.0
  1990–2006 11 6.1 947 22.1 <0.001 958 21.4
Years from diagnosis
  Mean 31.4  16.4   17.0  
  5–9 10 5.5 2044 47.6  2054 45.9
  10–19 31 17.1 1030 24.0  1061 23.7
  20–29 42 23.2 505 11.8  547 12.2
  30–39 45 24.9 372 8.7  417 9.3
  40–49 34 18.8 243 5.7  277 6.2
  50–59 17 9.4 86 2.0  103 2.3
  ≥60 2 1.1 14 0.3 <0.001 16 0.4
Attained age at exit, y
  Mean 39.2  23.7   24.3  
  5–9 1 0.6 415 9.7  416 9.3
(Continued )
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Overall, the cumulative mortality for cardiac death 
was 5.0% at 60 years of follow-up compared with 3.5% 
expected (Figure I in the online-only Data Supplement). 
Among the FPN types, the cumulative mortality was 
greatest for survivors of Wilms and HL (Figure 1); the cu-
mulative mortality for HL survivors began to increase at 
20 years of follow-up compared with 25 years of follow-
up in Wilms survivors and increased at a higher rate than 
that observed for Wilms survivors.
Cardiac-Specific Mortality
Of the 181 cardiac deaths observed, there were 96 IHD, 
52 CM/HF, 8 valvular disease, 5 arrhythmia, 2 pericar-
dial disease, and 18 other cardiac deaths (7 pulmonary 
heart disease, 4 acute/subacute infective endocarditis, 4 
cardiovascular disease unspecified, 1 hypertensive heart 
and renal disease, 1 hypertensive heart disease without 
heart failure, 1 other ill-defined heart disease; Table 2). 
The SMRs for IHD, CM/HF, valvular, arrhythmia, pericardi-
al, and other cardiac deaths were as follows: 2.5 (95% CI, 
2.0–3.1), 5.9 (95% CI, 4.4–7.7), 3.6 (95% CI, 1.6–7.2), 
3.4 (95% CI, 1.1–8.0), 8.0 (95% CI, 1.0–29.0), and 8.3 
(95% CI, 4.9–13.1), respectively. Because IHD and CM/
HF accounted for >80% of cardiac deaths overall, we con-
sider only these 2 specific cardiac outcomes separately.
IHD Mortality
The cumulative mortality of IHD deaths increased steadi-
ly until ≈45 years of follow-up, at which point there was a 
steeper increase, ultimately reaching 3.8% at 65 years 
of follow-up, which was 1.0% higher than expected (Fig-
ure I in the online-only Data Supplement). The SMR for 
IHD death was highest for survivors of Wilms (SMR, 5.3; 
95% CI, 2.7–9.5) and HL (SMR, 4.4; 95% CI, 2.7–6.8; 
Table 3). Survivors of central nervous system tumors 
(excluding primitive neuroectodermal tumor), non- 
Hodgkin lymphoma (NHL), and ‘other’ FPN types also 
had a statistically significant elevated risk of IHD death. 
As attained age increased, the SMR declined significant-
ly (P for trend=0.0344) and AER increased significantly 
(P for trend<0.0001); beyond 60 years of age, survivors 
remained >2 times (SMR, 2.3; 95% CI, 1.3–3.8) more 
at risk than expected, which equated to 22.2 (95% CI, 
3.2–41.1) excess IHD deaths per 10 000 person-years. 
There was no evidence of a relationship between treat-
ment era and the excess risk (multiplicative or additive) 
of IHD deaths (Table 4).
CM/HF Mortality
At 65 years from diagnosis, the cumulative mortality 
of CM/HF deaths was 0.5% compared with 0.3% ex-
pected (Figure I in the online-only Data Supplement). 
All FPN types with at least 5 observed CM/HF deaths 
were found to be at a substantially higher risk than 
expected of CM/HF death (SMR>5.0; Table 3); survi-
vors of acute myeloid leukemia, NHL, and Wilms were 
greatest at risk, with 66.0 times (95% CI, 28.5–130.0), 
10.2 times (95% CI, 3.7–22.2), and 8.0 times (95% CI, 
2.6–18.8) the number of expected CM/HF deaths, re-
spectively. After adjustment, there was no evidence of 
Table 2. Standardized Mortality Ratios and Absolute 
Excess Risks per 10 000 Person-Years for Deaths 
Resulting From All Cardiac Causes and Cardiac-
Specific Causes
 O/E SMR (95% CI) AER (95% CI)
Overall 181/53.1 3.4 (2.9–3.9) 2.1 (1.6–2.5)
IHD 96/38.2 2.5 (2.0–3.1) 0.9 (0.6–1.2)
CM/HF 52/8.9 5.9 (4.4–7.7) 0.7 (0.5–0.9)
Valvular 8/2.2 3.6 (1.6–7.2) 0.1 (0.0–0.2)
Arrhythmia 5/1.5 3.4 (1.1–8.0) 0.1 (0.0–0.1)
Pericardial 2/0.2 8.0 (1.0–29.0) 0.0 (0.0–0.1)
Other cardiac 18/2.2 8.3 (4.9–13.1) 0.3 (0.1–0.4)
AER indicates absolute excess risk; CI, confidence interval; CM/HF, 
cardiomyopathy/heart failure; E, expected; IHD, ischemic heart disease; O, 
observed; and SMR, standardized mortality ratio. 
  10–19 19 10.5 1812 42.2 1831 40.9
  20–29 33 18.2 970 22.6 1003 22.4
  30–39 42 23.2 493 11.5 535 12.0
  40–49 36 19.9 328 7.7 364 8.1
  50–59 32 17.7 206 4.8 238 5.3
  ≥60 18 9.9 70 1.6 <0.001 88 2.0
AML indicates acute myeloid leukemia; CNS, central nervous system; FPN, first primary neoplasm; HL, Hodgkin lymphoma; NHL, Non-Hodgkin lymphoma; 
and PNET, primitive neuroectodermal tumor.
Table 1. Continued
Patient Characteristic
Cardiac Deaths Other Deaths
P Value
Total
n % n % n %
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a linear increase or decrease in excess risk of CM/HF 
death with attained age (SMR P for trend=0.8121, AER 
P for trend=0.0591). However, with regard to treatment 
era, evidence of a quadratic relationship was found for 
both the SMRs (P for quadratic<0.0001) and AERs (P for 
quadratic<0.0001; Table 4). More specifically, the num-
ber of excess CM/HF deaths increased with treatment 
era beginning around 1970, peaked among those treat-
ed in the 1980s, and then subsequently declined among 
those treated more recently (Figure 2). After adjustment 
for sex, FPN type, age at diagnosis, and attained age, 
survivors diagnosed from 1970 to 1979, 1980 to 1989, 
and 1990 to 2006 had 13.9 times (95% CI, 1.1–168.5), 
28.9 times (95% CI, 2.4–354.6), and 4.5 times (95% 
CI, 0.3–69.4) more excess CM/HF deaths, respectively, 
than survivors diagnosed before 1970 (Table 4).
Table 3. Standardized Mortality Ratios and Absolute Excess Risks per 10 000 Person-Years for Overall Cardiac Mortality, 
Ischemic Heart Disease Mortality, and Cardiomyopathy/Heart Failure Mortality, by Potential Explanatory Factors Table 3. Continued
Person-Years
Overall Cardiac Mortality IHD Mortality CM/HF Mortality
O/E SMR (95% CI) AER (95% CI) O/E SMR (95% CI) AER (95% CI) O/E SMR (95% CI) AER (95% CI)
Overall 620 753 181/53.1 3.4 (2.9 to 3.9) 2.1 (1.6 to 2.5) 96/38.2 2.5 (2.0 to 3.1) 0.9 (0.6 to 1.2) 52/8.9 5.9 (4.4 to 7.7) 0.7 (0.5 to 0.9)
Sex
  Male 336 802 115/42.2 2.7 (2.2 to 3.3) 2.2 (1.5 to 2.8) 70/31.6 2.2 (1.7 to 2.8) 1.1 (0.7 to 1.6) 27/6.6 4.1 (2.7 to 6.0) 0.6 (0.3 to 0.9)
  Female 283 951 66/10.9 6.0 (4.7 to 7.7) 1.9 (1.4 to 2.5) 26/6.6 4.0 (2.6 to 5.8) 0.7 (0.3 to 1.0) 25/2.3 10.9 (7.0 to 16.0) 0.8 (0.5 to 1.1)
  P for heterogeneity   <0.0001 0.7771  0.0091 0.2600  0.0002 0.2179
FPN type
  CNS (excluding PNET) 124 750 32/13.9 2.3 (1.6 to 3.3) 1.5 (0.6 to 2.3) 20/10.4 1.9 (1.2 to 3.0) 0.8 (0.1 to 1.5) 4/2.0 2.0 (0.5 to 5.0) 0.2 (−0.2 to 0.5)
  CNS PNET 18 694 5/1.5 3.3 (1.1 to 7.6) 1.9 (−0.5 to 4.2) 4/1.1 3.7 (1.0 to 9.5) 1.6 (−0.5 to 3.7) 1/0.3 3.7 (0.1 to 20.5) 0.4 (−0.7 to 1.4)
  Leukemia (excluding AML) 145 237 17/4.4 3.9 (2.3 to 6.2) 0.9 (0.3 to 1.4) 3/2.2 1.4 (0.3 to 4.0) 0.1 (−0.2 to 0.3) 10/1.4 7.2 (3.5 to 13.3) 0.6 (0.2 to 1.0)
  AML 13 029 10/0.4 23.5 (11.2 to 43.1) 7.3 (2.6 to 12.1) 1/0.2 4.3 (0.1 to 24.0) 0.6 (−0.9 to 2.1) 8/0.1 66.0 (28.5 to 130.0) 6.0 (1.8 to 10.3)
  HL 42 600 33/6.1 5.4 (3.7 to 7.6) 6.3 (3.7 to 9.0) 20/4.6 4.4 (2.7 to 6.8) 3.6 (1.6 to 5.7) 6/0.9 6.7 (2.5 to 14.6) 1.2 (0.1 to 2.3)
  NHL 30 343 17/4.1 4.2 (2.4 to 6.6) 4.3 (1.6 to 6.9) 8/3.1 2.6 (1.1 to 5.1) 1.6 (−0.2 to 3.4) 6/0.6 10.2 (3.7 to 22.2) 1.8 (0.2 to 3.4)
  Neuroblastoma 28 500 4/1.7 2.4 (0.7 to 6.2) 0.8 (−0.6 to 2.2) 1/1.2 0.9 (0.0 to 4.8) −0.1 (−0.7 to 0.6) 1/0.3 3.3 (0.1 to 18.1) 0.2 (−0.4 to 0.9)
  Nonheritable retinoblastoma 26 167 2/2.8 0.7 (0.1 to 2.6) −0.3 (−1.4 to 0.8) 2/2.1 0.9 (0.1 to 3.4) −0.0 (−1.1 to 1.0) 0/0.4 - -
  Heritable retinoblastoma 20 162 4/1.9 2.1 (0.6 to 5.4) 1.0 (−0.9 to 3.0) 4/1.4 2.9 (0.8 to 7.4) 1.3 (−0.6 to 3.2) 0/0.3 - -
  Wilms 51 519 20/3.1 6.5 (4.0 to 10.0) 3.3 (1.6 to 5.0) 11/2.1 5.3 (2.7 to 9.5) 1.7 (0.5 to 3.0) 5/0.6 8.0 (2.6 to 18.8) 0.8 (−0.0 to 1.7)
  Bone sarcoma 21 798 9/3.1 2.9 (1.3 to 5.4) 2.7 (−0.0 to 5.4) 5/2.4 2.1 (0.7 to 4.9) 1.2 (−0.8 to 3.2) 2/0.4 4.7 (0.6 to 16.9) 0.7 (−0.6 to 2.0)
  Soft tissue sarcoma 42 062 12/4.8 2.5 (1.3 to 4.3) 1.7 (0.1 to 3.3) 7/3.6 1.9 (0.8 to 4.0) 0.8 (−0.4 to 2.0) 5/0.7 7.1 (2.3 to 16.7) 1.0 (−0.0 to 2.1)
  Other 55 891 16/5.3 3.0 (1.7 to 4.9) 1.9 (0.5 to 3.3) 10/3.9 2.6 (1.2 to 4.8) 1.1 (−0.0 to 2.2) 4/0.8 4.7 (1.3 to 12.1) 0.6 (−0.1 to 1.3)
  P for heterogeneity   <0.0001 <0.0001  0.0412 0.0760  0.0003 0.0002
Age at diagnosis, y
  0–4 291 564 63/14.9 4.2 (3.2 to 5.4) 1.6 (1.1 to 2.2) 26/9.9 2.6 (1.7 to 3.9) 0.6 (0.2 to 0.9) 22/3.1 7.1 (4.4 to 10.7) 0.6 (0.3 to 1.0)
  5–9 163 190 46/13.0 3.5 (2.6 to 4.7) 2.0 (1.2 to 2.8) 24/9.1 2.6 (1.7 to 3.9) 0.9 (0.3 to 1.5) 14/2.4 5.9 (3.2 to 9.9) 0.7 (0.3 to 1.2)
  10–14 165 999 72/25.2 2.9 (2.2 to 3.6) 2.8 (1.8 to 3.8) 46/19.2 2.4 (1.8 to 3.2) 1.6 (0.8 to 2.4) 16/3.4 4.7 (2.7 to 7.6) 0.8 (0.3 to 1.2)
  P for trend   0.0078 0.0211  0.5110 0.8914  0.0666 0.0986
Attained age, y
  5–19 243 030 20/2.1 9.7 (5.9 to 15.0) 0.7 (0.4 to 1.1) 1/0.1 8.0 (0.2 to 44.6) 0.0 (−0.0 to 0.1) 12/1.2 9.7 (5.0 to 16.9) 0.4 (0.2 to 0.7)
  20–29 195 584 33/4.2 7.8 (5.4 to 11.0) 1.5 (0.9 to 2.0) 12/1.2 10.0 (5.2 to 17.5) 0.6 (0.2 to 0.9) 16/1.9 8.6 (4.9 to 14.0) 0.7 (0.3 to 1.1)
  30–39 108 573 42/8.5 5.0 (3.6 to 6.7) 3.1 (1.9 to 4.3) 18/5.4 3.4 (2.0 to 5.3) 1.2 (0.4 to 1.9) 16/1.9 8.5 (4.9 to 13.8) 1.3 (0.6 to 2.0)
  40–49 51 869 36/15.4 2.3 (1.6 to 3.2) 4.0 (1.7 to 6.2) 24/12.3 2.0 (1.3 to 2.9) 2.3 (0.4 to 4.1) 3/1.9 1.6 (0.3 to 4.6) 0.2 (−0.4 to 0.9)
  50–59 17 552 32/14.8 2.2 (1.5 to 3.1) 9.8 (3.5 to 16.1) 25/12.4 2.0 (1.3 to 3.0) 7.2 (1.6 to 12.7) 4/1.3 3.0 (0.8 to 7.7) 1.5 (−0.7 to 3.8)
  ≥60 4144 18/8.2 2.2 (1.3 to 3.5) 23.7 (3.6 to 43.8) 16/6.8 2.3 (1.3 to 3.8) 22.2 (3.2 to 41.1) 1/0.7 1.5 (0.0 to 8.3) 0.8 (−3.9 to 5.5)
  P for trend   0.0065 <0.0001  0.0344 <0.0001  0.8121 0.0591
(Continued ) AER indicates absolute excess risk; AML, acute myeloid leukemia; CI, confidence interval; CM/HF, cardiomyopathy/heart failure; CNS, central nervous 
system; E, expected; FPN, first primary neoplasm; HL, Hodgkin lymphoma; IHD, ischemic heart disease; NHL, Non-Hodgkin lymphoma; O, observed; 
PNET, primitive neuroectodermal tumor; and SMR, standardized mortality ratio. All P values were calculated with a multivariable Poisson regression model 
adjusted for sex, FPN type, age at diagnosis, treatment era, and attained age.
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DISCUSSION
This largest ever study of cardiac mortality after child-
hood cancer within a cohort of 34 489 five-year survi-
vors provides an unprecedented opportunity to investi-
gate the impact of treatment era on the risk of cardiac 
death. Furthermore, with 73 565 person-years and 86 
cardiac deaths among those >40 years of age and 
21 696 person-years and 50 cardiac deaths among 
those >50 years of age, this is the first study to 
Table 3. Standardized Mortality Ratios and Absolute Excess Risks per 10 000 Person-Years for Overall Cardiac Mortality, 
Ischemic Heart Disease Mortality, and Cardiomyopathy/Heart Failure Mortality, by Potential Explanatory Factors Table 3. Continued
Person-Years
Overall Cardiac Mortality IHD Mortality CM/HF Mortality
O/E SMR (95% CI) AER (95% CI) O/E SMR (95% CI) AER (95% CI) O/E SMR (95% CI) AER (95% CI)
Overall 620 753 181/53.1 3.4 (2.9 to 3.9) 2.1 (1.6 to 2.5) 96/38.2 2.5 (2.0 to 3.1) 0.9 (0.6 to 1.2) 52/8.9 5.9 (4.4 to 7.7) 0.7 (0.5 to 0.9)
Sex
  Male 336 802 115/42.2 2.7 (2.2 to 3.3) 2.2 (1.5 to 2.8) 70/31.6 2.2 (1.7 to 2.8) 1.1 (0.7 to 1.6) 27/6.6 4.1 (2.7 to 6.0) 0.6 (0.3 to 0.9)
  Female 283 951 66/10.9 6.0 (4.7 to 7.7) 1.9 (1.4 to 2.5) 26/6.6 4.0 (2.6 to 5.8) 0.7 (0.3 to 1.0) 25/2.3 10.9 (7.0 to 16.0) 0.8 (0.5 to 1.1)
  P for heterogeneity   <0.0001 0.7771  0.0091 0.2600  0.0002 0.2179
FPN type
  CNS (excluding PNET) 124 750 32/13.9 2.3 (1.6 to 3.3) 1.5 (0.6 to 2.3) 20/10.4 1.9 (1.2 to 3.0) 0.8 (0.1 to 1.5) 4/2.0 2.0 (0.5 to 5.0) 0.2 (−0.2 to 0.5)
  CNS PNET 18 694 5/1.5 3.3 (1.1 to 7.6) 1.9 (−0.5 to 4.2) 4/1.1 3.7 (1.0 to 9.5) 1.6 (−0.5 to 3.7) 1/0.3 3.7 (0.1 to 20.5) 0.4 (−0.7 to 1.4)
  Leukemia (excluding AML) 145 237 17/4.4 3.9 (2.3 to 6.2) 0.9 (0.3 to 1.4) 3/2.2 1.4 (0.3 to 4.0) 0.1 (−0.2 to 0.3) 10/1.4 7.2 (3.5 to 13.3) 0.6 (0.2 to 1.0)
  AML 13 029 10/0.4 23.5 (11.2 to 43.1) 7.3 (2.6 to 12.1) 1/0.2 4.3 (0.1 to 24.0) 0.6 (−0.9 to 2.1) 8/0.1 66.0 (28.5 to 130.0) 6.0 (1.8 to 10.3)
  HL 42 600 33/6.1 5.4 (3.7 to 7.6) 6.3 (3.7 to 9.0) 20/4.6 4.4 (2.7 to 6.8) 3.6 (1.6 to 5.7) 6/0.9 6.7 (2.5 to 14.6) 1.2 (0.1 to 2.3)
  NHL 30 343 17/4.1 4.2 (2.4 to 6.6) 4.3 (1.6 to 6.9) 8/3.1 2.6 (1.1 to 5.1) 1.6 (−0.2 to 3.4) 6/0.6 10.2 (3.7 to 22.2) 1.8 (0.2 to 3.4)
  Neuroblastoma 28 500 4/1.7 2.4 (0.7 to 6.2) 0.8 (−0.6 to 2.2) 1/1.2 0.9 (0.0 to 4.8) −0.1 (−0.7 to 0.6) 1/0.3 3.3 (0.1 to 18.1) 0.2 (−0.4 to 0.9)
  Nonheritable retinoblastoma 26 167 2/2.8 0.7 (0.1 to 2.6) −0.3 (−1.4 to 0.8) 2/2.1 0.9 (0.1 to 3.4) −0.0 (−1.1 to 1.0) 0/0.4 - -
  Heritable retinoblastoma 20 162 4/1.9 2.1 (0.6 to 5.4) 1.0 (−0.9 to 3.0) 4/1.4 2.9 (0.8 to 7.4) 1.3 (−0.6 to 3.2) 0/0.3 - -
  Wilms 51 519 20/3.1 6.5 (4.0 to 10.0) 3.3 (1.6 to 5.0) 11/2.1 5.3 (2.7 to 9.5) 1.7 (0.5 to 3.0) 5/0.6 8.0 (2.6 to 18.8) 0.8 (−0.0 to 1.7)
  Bone sarcoma 21 798 9/3.1 2.9 (1.3 to 5.4) 2.7 (−0.0 to 5.4) 5/2.4 2.1 (0.7 to 4.9) 1.2 (−0.8 to 3.2) 2/0.4 4.7 (0.6 to 16.9) 0.7 (−0.6 to 2.0)
  Soft tissue sarcoma 42 062 12/4.8 2.5 (1.3 to 4.3) 1.7 (0.1 to 3.3) 7/3.6 1.9 (0.8 to 4.0) 0.8 (−0.4 to 2.0) 5/0.7 7.1 (2.3 to 16.7) 1.0 (−0.0 to 2.1)
  Other 55 891 16/5.3 3.0 (1.7 to 4.9) 1.9 (0.5 to 3.3) 10/3.9 2.6 (1.2 to 4.8) 1.1 (−0.0 to 2.2) 4/0.8 4.7 (1.3 to 12.1) 0.6 (−0.1 to 1.3)
  P for heterogeneity   <0.0001 <0.0001  0.0412 0.0760  0.0003 0.0002
Age at diagnosis, y
  0–4 291 564 63/14.9 4.2 (3.2 to 5.4) 1.6 (1.1 to 2.2) 26/9.9 2.6 (1.7 to 3.9) 0.6 (0.2 to 0.9) 22/3.1 7.1 (4.4 to 10.7) 0.6 (0.3 to 1.0)
  5–9 163 190 46/13.0 3.5 (2.6 to 4.7) 2.0 (1.2 to 2.8) 24/9.1 2.6 (1.7 to 3.9) 0.9 (0.3 to 1.5) 14/2.4 5.9 (3.2 to 9.9) 0.7 (0.3 to 1.2)
  10–14 165 999 72/25.2 2.9 (2.2 to 3.6) 2.8 (1.8 to 3.8) 46/19.2 2.4 (1.8 to 3.2) 1.6 (0.8 to 2.4) 16/3.4 4.7 (2.7 to 7.6) 0.8 (0.3 to 1.2)
  P for trend   0.0078 0.0211  0.5110 0.8914  0.0666 0.0986
Attained age, y
  5–19 243 030 20/2.1 9.7 (5.9 to 15.0) 0.7 (0.4 to 1.1) 1/0.1 8.0 (0.2 to 44.6) 0.0 (−0.0 to 0.1) 12/1.2 9.7 (5.0 to 16.9) 0.4 (0.2 to 0.7)
  20–29 195 584 33/4.2 7.8 (5.4 to 11.0) 1.5 (0.9 to 2.0) 12/1.2 10.0 (5.2 to 17.5) 0.6 (0.2 to 0.9) 16/1.9 8.6 (4.9 to 14.0) 0.7 (0.3 to 1.1)
  30–39 108 573 42/8.5 5.0 (3.6 to 6.7) 3.1 (1.9 to 4.3) 18/5.4 3.4 (2.0 to 5.3) 1.2 (0.4 to 1.9) 16/1.9 8.5 (4.9 to 13.8) 1.3 (0.6 to 2.0)
  40–49 51 869 36/15.4 2.3 (1.6 to 3.2) 4.0 (1.7 to 6.2) 24/12.3 2.0 (1.3 to 2.9) 2.3 (0.4 to 4.1) 3/1.9 1.6 (0.3 to 4.6) 0.2 (−0.4 to 0.9)
  50–59 17 552 32/14.8 2.2 (1.5 to 3.1) 9.8 (3.5 to 16.1) 25/12.4 2.0 (1.3 to 3.0) 7.2 (1.6 to 12.7) 4/1.3 3.0 (0.8 to 7.7) 1.5 (−0.7 to 3.8)
  ≥60 4144 18/8.2 2.2 (1.3 to 3.5) 23.7 (3.6 to 43.8) 16/6.8 2.3 (1.3 to 3.8) 22.2 (3.2 to 41.1) 1/0.7 1.5 (0.0 to 8.3) 0.8 (−3.9 to 5.5)
  P for trend   0.0065 <0.0001  0.0344 <0.0001  0.8121 0.0591
(Continued ) AER indicates absolute excess risk; AML, acute myeloid leukemia; CI, confidence interval; CM/HF, cardiomyopathy/heart failure; CNS, central nervous 
system; E, expected; FPN, first primary neoplasm; HL, Hodgkin lymphoma; IHD, ischemic heart disease; NHL, Non-Hodgkin lymphoma; O, observed; 
PNET, primitive neuroectodermal tumor; and SMR, standardized mortality ratio. All P values were calculated with a multivariable Poisson regression model 
adjusted for sex, FPN type, age at diagnosis, treatment era, and attained age.
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 satisfactorily assess the pattern of excess cardiac 
deaths among survivors >50 years old. In doing so, 
this study adds 250 728 person-years and 76 cardiac 
deaths to our previous largest study assessing cardiac 
mortality.14 Furthermore, this study expands on and ad-
dresses many of the limitations of previous work assess-
ing mortality among childhood cancer survivors from the 
United States3,4,15 and Nordic countries.16,17
Principal Findings and Comparisons With Other 
Studies
Although 2 previous studies have assessed trends in 
the risk of cardiac causes of death among 5-year survi-
vors of childhood cancer in relation to treatment era,3,4 
this is the first study to provide evidence of a qua-
dratic relationship for the excess risk of cardiac death 
overall and for CM/HF death in relation to treatment 
era, for which the number of excess deaths increases 
with treatment era, peaks among those treated in the 
1980s, and then subsequently declines among those 
treated more recently. This relationship corresponds 
closely to the introduction of anthracycline chemo-
therapy, which has been shown to increase the risk 
of dilated cardiomyopathy18–20 and congestive heart 
failure.21 However, these results differ from a CCSS 
report3 that found a significant decline in the adjusted 
relative rate of death resulting from cardiac causes 
with more recent treatment era. Although the CCSS 
has a more restricted diagnosis period (1970–1999, 
30 years) compared with our study (1940–2006, 66 
years), it is unlikely that this explains the difference 
observed because we did not observe a linear decline 
in excess cardiac deaths with treatment era after re-
stricting our diagnosis period to match the CCSS (SMR 
P for trend=0.7687, AER P for trend=0.3521; Table VI 
in the online-only Data Supplement). In fact, a quadratic 
relationship between treatment era and excess cardiac 
deaths was observed in the BCCSS when the diagno-
sis period was restricted to 1970 to 1999 (SMR P 
Table 4. Standardized Mortality Ratios and Corresponding Relative Risks and Absolute Excess Risks per 
10 000 Person-Years and Corresponding Excess Mortality Ratios for Each Treatment Era Table 4. Continued
Treatment 
Era
Overall Cardiac Mortality IHD Mortality IHD Mortality Continued CM/HF Mortality
O/E SMR (95% CI) RR (95% CI) AER (95% CI) EMR (95% CI) O/E SMR (95% CI) RR (95% CI) AER (95% CI) EMR (95% CI) O/E SMR (95% CI) RR (95% CI) AER (95% CI) EMR (95% CI)
Before 1970 79/35.6 2.2 (1.8 to 2.8) 1 (Ref) 3.2 (1.9 to 4.5) 1 (Ref) 62/28.8 2.2 (1.7 to 2.8) 1 (Ref) 2.4 (1.3 to 3.6) 1 (Ref) 4/3.7 1.1 (0.3 to 2.7) 1 (Ref) 0.0 (−0.3 to 0.3) 1 (Ref)
1970–1979 48/10.7 4.5 (3.3 to 5.9) 1.6 (1.0 to 2.5) 2.4 (1.6 to 3.3) 1.3 (0.7 to 2.4) 25/6.9 3.6 (2.4 to 5.4) 1.5 (0.9 to 2.6) 1.2 (0.5 to 1.8) 1.0 (0.4 to 2.2) 16/2.4 6.5 (3.7 to 10.6) 8.9 (2.1 to 37.8) 0.9 (0.4 to 1.4) 13.9 (1.1 to 168.5)
1980–1989 43/4.7 9.1 (6.6 to 12.3) 2.3 (1.4 to 3.9) 2.5 (1.6 to 3.3) 1.8 (0.9 to 3.5) 6/2.1 2.9 (1.1 to 6.2) 0.8 (0.3 to 2.0) 0.3 (−0.1 to 0.6) 0.3 (0.1 to 1.4) 28/1.7 16.7 (11.1 to 24.1) 18.2 (3.9 to 84.2) 1.7 (1.0 to 2.4) 28.9 (2.4 to 354.6)
1990–2006 11/2.1 5.2 (2.6 to 9.4) 1.0 (0.4 to 2.1) 0.5 (0.1 to 0.9) 0.6 (0.2 to 1.5) 3/0.4 7.1 (1.5 to 20.6) 1.0 (0.3 to 3.8) 0.1 (−0.0 to 0.3) 0.4 (0.1 to 2.0) 4/1.0 3.9 (1.1 to 10.0) 3.7 (0.6 to 23.3) 0.2 (−0.1 to 0.4) 4.5 (0.3 to 69.4)
P for trend  0.1318 0.8583  0.9171 0.1098  0.1231 0.3453
P  for quadratic  0.0014 0.0072  0.2518 0.6850  <0.0001 <0.0001
(Continued ) AER indicates absolute excess risk; CI, confidence interval; CM/HF, cardiomyopathy/heart failure; E, expected; EMR, excess mortality ratio; IHD, ischemic 
heart disease; O, observed; Ref, referent; RR, relative risk; and SMR, standardized mortality ratio. RR, EMRs, and all P values were estimated with a 
multivariable Poisson regression model adjusted for sex, first primary neoplasm type, age at diagnosis, treatment era, and attained age.
Table 5. Absolute Excess Risks for Recurrences/Progression, Subsequent Primary Neoplasms, Nonneoplastic, 
Cardiac, Other Circulatory, and Other Nonneoplastic Causes of Death, by Attained Age as a Proportion of Total 
Excess Risk Table 5. Continued
Attained Age, y Attained Age, y Continued
5–19 20–29 30–39 40–49 50–59 ≥60
O/E AER % Total O/E AER % Total O/E AER % Total O/E AER % Total O/E AER % Total O/E AER % Total
Recurrence/progression 1835/0.0 75.5 84.3 553/0.0 28.3 62.1 161/0.0 14.8 36.5 52/0.0 10.0 19.3 18/0.0 10.3 11.2 7/0.0 16.9 15.6
Subsequent primary neoplasms 184/10.1 7.2 8.0 184/13.7 8.7 19.1 163/20.2 13.1 32.3 131/30.5 19.4 37.4 99/32.5 37.9 41.1 34/19.9 33.9 31.4
Nonneoplastic 228/60.4 6.9 7.7 266/97.5 8.6 18.9 211/74.6 12.6 31.1 181/64.6 22.4 43.2 121/43.6 44.1 47.8 47/23.3 57.3 53.0
  Cardiac 20/2.1 0.7 0.8 33/4.2 1.5 3.3 42/8.5 3.1 7.7 36/15.4 4.0 7.7 32/14.8 9.8 10.6 18/8.2 23.7 21.9
  Other circulatory 10/1.4 0.4 0.4 23/3.4 1.0 3.2 21/5.1 1.5 3.7 32/6.4 4.9 9.4 23/5.2 10.1 11.0 10/3.3 16.1 14.9
  Other nonneoplastic* 198/56.9 5.8 0.5 210/89.9 6.1 13.4 148/61.0 8.0 19.8 113/42.8 13.5 26.0 66/23.6 24.2 16.2 19/11.8 17.5 16.2
All causes 2247/70.5 89.6 100.0 1003/111.2 45.6 100.0 535/94.8 40.5 100.0 364/95.1 51.9 100.0 238/76.1 92.2 100.0 88/43.2 108.1 100.0
(Continued ) AER indicates absolute excess risk; E, expected; and O, observed. 
*Includes the following causes of death: respiratory, nervous, infection, digestive, perinatal, endocrine, genitourinary, musculoskeletal, mental, blood, 
external, and other.
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for  quadratic=0.0024, AER P for quadratic=0.0019). 
A possible explanation for the difference observed be-
tween the BCCSS and CCSS would be differences in 
childhood cancer treatment exposures related to the 
development of cardiac diseases between the 2 stud-
ies. However, it is not possible to explore this hypoth-
esis because of the lack of detailed treatment informa-
tion for the BCCSS.
Overall, cardiac mortality estimates in this cohort 
were elevated at 3 times that expected. The risk of 
cardiac death remained elevated beyond 60 years of 
age, and the number of excess cardiac deaths was 
observed to increase significantly with age. Among 
those >60 years of age, cardiac deaths accounted 
for 22% and 41% of all excess deaths and all non-
neoplastic excess deaths, respectively. This finding 
provides evidence that as survivors age beyond 60 
years, circulatory deaths account for more excess 
deaths, 37% (60% of which was due to cardiac 
causes), than SPNs, 31%. With 31%, 22%, and 15% 
(in total 68%) of all excess deaths among those >60 
years of age attributable to SPNs, cardiac disease, 
and other circulatory conditions, respectively, there 
is a clear message in terms of prevention of prema-
ture morbidity and mortality: Specific interventions, 
in terms of surveillance and treatment, that reduce 
SPNs and circulatory disease in survivors of child-
hood cancer are needed.
Another finding worth noting from our study relates 
to the risk of cardiac death by FPN type. Although HL 
survivors have long been recognized as having an in-
creased risk of cardiac death, leading much research 
to focus on these survivors,22–24 Wilms survivors were 
in fact found to have a greater risk of cardiac death 
than HL survivors. In particular, Wilms survivors were 
found to have the greatest risk of IHD death among 
all FPN types; this finding suggests that hyperten-
sion and having 1 kidney are strong risk factors in 
Wilms survivors for cardiac death because the car-
diac radiotherapy exposure in these survivors would 
be expected to be much lower than that used for HL 
survivors.
Table 4. Standardized Mortality Ratios and Corresponding Relative Risks and Absolute Excess Risks per 
10 000 Person-Years and Corresponding Excess Mortality Ratios for Each Treatment Era Table 4. Continued
Treatment 
Era
Overall Cardiac Mortality IHD Mortality IHD Mortality Continued CM/HF Mortality
O/E SMR (95% CI) RR (95% CI) AER (95% CI) EMR (95% CI) O/E SMR (95% CI) RR (95% CI) AER (95% CI) EMR (95% CI) O/E SMR (95% CI) RR (95% CI) AER (95% CI) EMR (95% CI)
Before 1970 79/35.6 2.2 (1.8 to 2.8) 1 (Ref) 3.2 (1.9 to 4.5) 1 (Ref) 62/28.8 2.2 (1.7 to 2.8) 1 (Ref) 2.4 (1.3 to 3.6) 1 (Ref) 4/3.7 1.1 (0.3 to 2.7) 1 (Ref) 0.0 (−0.3 to 0.3) 1 (Ref)
1970–1979 48/10.7 4.5 (3.3 to 5.9) 1.6 (1.0 to 2.5) 2.4 (1.6 to 3.3) 1.3 (0.7 to 2.4) 25/6.9 3.6 (2.4 to 5.4) 1.5 (0.9 to 2.6) 1.2 (0.5 to 1.8) 1.0 (0.4 to 2.2) 16/2.4 6.5 (3.7 to 10.6) 8.9 (2.1 to 37.8) 0.9 (0.4 to 1.4) 13.9 (1.1 to 168.5)
1980–1989 43/4.7 9.1 (6.6 to 12.3) 2.3 (1.4 to 3.9) 2.5 (1.6 to 3.3) 1.8 (0.9 to 3.5) 6/2.1 2.9 (1.1 to 6.2) 0.8 (0.3 to 2.0) 0.3 (−0.1 to 0.6) 0.3 (0.1 to 1.4) 28/1.7 16.7 (11.1 to 24.1) 18.2 (3.9 to 84.2) 1.7 (1.0 to 2.4) 28.9 (2.4 to 354.6)
1990–2006 11/2.1 5.2 (2.6 to 9.4) 1.0 (0.4 to 2.1) 0.5 (0.1 to 0.9) 0.6 (0.2 to 1.5) 3/0.4 7.1 (1.5 to 20.6) 1.0 (0.3 to 3.8) 0.1 (−0.0 to 0.3) 0.4 (0.1 to 2.0) 4/1.0 3.9 (1.1 to 10.0) 3.7 (0.6 to 23.3) 0.2 (−0.1 to 0.4) 4.5 (0.3 to 69.4)
P for trend  0.1318 0.8583  0.9171 0.1098  0.1231 0.3453
P  for quadratic  0.0014 0.0072  0.2518 0.6850  <0.0001 <0.0001
(Continued ) AER indicates absolute excess risk; CI, confidence interval; CM/HF, cardiomyopathy/heart failure; E, expected; EMR, excess mortality ratio; IHD, ischemic 
heart disease; O, observed; Ref, referent; RR, relative risk; and SMR, standardized mortality ratio. RR, EMRs, and all P values were estimated with a 
multivariable Poisson regression model adjusted for sex, first primary neoplasm type, age at diagnosis, treatment era, and attained age.
Table 5. Absolute Excess Risks for Recurrences/Progression, Subsequent Primary Neoplasms, Nonneoplastic, 
Cardiac, Other Circulatory, and Other Nonneoplastic Causes of Death, by Attained Age as a Proportion of Total 
Excess Risk Table 5. Continued
Attained Age, y Attained Age, y Continued
5–19 20–29 30–39 40–49 50–59 ≥60
O/E AER % Total O/E AER % Total O/E AER % Total O/E AER % Total O/E AER % Total O/E AER % Total
Recurrence/progression 1835/0.0 75.5 84.3 553/0.0 28.3 62.1 161/0.0 14.8 36.5 52/0.0 10.0 19.3 18/0.0 10.3 11.2 7/0.0 16.9 15.6
Subsequent primary neoplasms 184/10.1 7.2 8.0 184/13.7 8.7 19.1 163/20.2 13.1 32.3 131/30.5 19.4 37.4 99/32.5 37.9 41.1 34/19.9 33.9 31.4
Nonneoplastic 228/60.4 6.9 7.7 266/97.5 8.6 18.9 211/74.6 12.6 31.1 181/64.6 22.4 43.2 121/43.6 44.1 47.8 47/23.3 57.3 53.0
  Cardiac 20/2.1 0.7 0.8 33/4.2 1.5 3.3 42/8.5 3.1 7.7 36/15.4 4.0 7.7 32/14.8 9.8 10.6 18/8.2 23.7 21.9
  Other circulatory 10/1.4 0.4 0.4 23/3.4 1.0 3.2 21/5.1 1.5 3.7 32/6.4 4.9 9.4 23/5.2 10.1 11.0 10/3.3 16.1 14.9
  Other nonneoplastic* 198/56.9 5.8 0.5 210/89.9 6.1 13.4 148/61.0 8.0 19.8 113/42.8 13.5 26.0 66/23.6 24.2 16.2 19/11.8 17.5 16.2
All causes 2247/70.5 89.6 100.0 1003/111.2 45.6 100.0 535/94.8 40.5 100.0 364/95.1 51.9 100.0 238/76.1 92.2 100.0 88/43.2 108.1 100.0
(Continued ) AER indicates absolute excess risk; E, expected; and O, observed. 
*Includes the following causes of death: respiratory, nervous, infection, digestive, perinatal, endocrine, genitourinary, musculoskeletal, mental, blood, 
external, and other.
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Special Consideration
Despite the increased risk of cardiac death reported in 
this study during the 1980s, it is important to recognize 
that many more children diagnosed with cancer in the 
1980s have survived as a result of anthracycline che-
motherapy than have died as a result of its late effects. 
Furthermore, the fact that the excess risk of cardiac 
death has subsequently declined in those diagnosed in 
the 1990s and 2000s suggests that measures to re-
duce cardiotoxicity through the use of alternative drugs, 
lower cumulative doses, and improved monitoring and 
intervention appears to be having a beneficial effect for 
those treated more recently.
Strengths and Weaknesses
The main strengths of our study are its large size, popula-
tion-based design, wide diagnosis period, and long avail-
able follow-up time, which have provided an exceptional 
opportunity to assess cardiac mortality after childhood 
cancer. Through these strengths, we have been able to 
assess the impact of cancer treatment on cardiac mortal-
ity from prechemotherapy treatment eras to modern ther-
apies and protocols. We have also been able to provide 
for the first time results on the risk of cardiac mortality 
among survivors of childhood cancer beyond 60 years of 
age. Because selection bias will be minimized through our 
population-based study design, these results are gener-
alizable to survivors of childhood cancer in Great Britain, 
as well as other childhood cancer populations provided 
that they were treated with similar therapies. Therefore, 
the findings of this study provide useful evidence for sur-
vivors, clinicians, and clinical follow-up guidelines in Great 
Britain and potentially internationally.
A weakness of our study is the lack of detailed radio-
therapy and chemotherapy information, which precluded 
any examination of dose-response patterns of treatment 
exposures in relation to cardiac mortality risk. However, 
the large-scale population-based design, wide spectrum 
of treatment eras, and very long follow-up available in 
this study provide opportunities not available in other 
cohorts. Another possible limitation of this study is that 
our classification of cardiac death relied on the under-
lying cause of death as listed on the death certificate, 
which has been previously shown to have imperfect 
accuracy.25–28 Although there is possible misclassifica-
Figure 1. Cumulative mortality for cardiac death by first primary neoplasm (FPN) diagnostic groups, by follow-
up (years since diagnosis), compared with that expected. 
HL indicates Hodgkin lymphoma.
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tion, it is more likely that we have underascertained 
cardiac deaths and thus underestimated the risk of car-
diac death among childhood cancer survivors because 
these individuals are more likely to be coded as having 
a neoplastic-related death resulting from their previous 
medical history.16
Reassessment of Findings
Over the treatment eras covered by this study, survival 
has improved substantially, and treatment regimens have 
changed markedly. Because of these evolving changes 
in survival and treatment exposures, reassessment of 
cardiac mortality after childhood cancer is crucial. For 
example, although we observed that the risk of cardiac 
death was greatest among those treated in the 1980s, 
it is important to determine whether with additional fol-
low-up the more recently diagnosed survivors remain at 
a decreased risk or whether cardiac death has merely 
been delayed as a result of increased awareness, sur-
veillance, and treatment of late effects after known car-
diotoxic exposures. Similarly, we observed that cardiac 
death became one of the principal contributors to the 
excess number of deaths beyond 60 years of age. How-
ever, the survivors at least 60 years old at the time of 
our study are quite different from those more recently di-
agnosed in terms of both FPN types and treatment expo-
sures. Therefore, a reassessment of the mortality risks 
in survivors >60 years of age is necessary in the future 
to determine the generalizability of our results for future 
childhood cancer survivors who reach 60 years of age.
Future Research
At present, the Center for Childhood Cancer Survivor 
Studies is involved in several investigations aimed at im-
proving knowledge of the risks and causes of cardiovas-
cular complications among childhood cancer survivors. In 
particular, the center is collaborating in PanCareSurFup29 
and PROCARDIO,30 both European consortiums investi-
gating the link between cardiovascular disease and expo-
sure of the heart and major vessels to radiotherapy and 
chemotherapy. For these projects, detailed treatment re-
cords were collected, and cumulative doses of radiation 
from radiotherapy and of each anticancer drug are being 
calculated. The resultant case-control studies will enable 
investigation of the dose-response between radiation and 
chemotherapy exposure of the heart and the risk of heart 
disease. The BCCSS cohort has also been linked to the 
national database of Hospital Episode Statistics, which is 
an electronic health record system for all hospitalizations 
in England. Through this linkage, the BCCSS will be in a 
stronger position to understand cardiac morbidity, and its 
treatment, in childhood cancer survivors. As a result of 
such initiatives, the BCCSS will be able to provide further 
insight into cardiovascular late effects among childhood 
cancer survivors in the United Kingdom.
Conclusions and Implications
The greatest excess risks for deaths from CM/HF were 
observed among those treated between 1980 and 
1989, which suggests that initiatives to reduce cardio-
toxicity among those treated more recently may be hav-
ing a measurable impact. Among those >60 years of 
age, SPNs, cardiac disease, and other circulatory condi-
tions accounted for 31%, 22%, and 15% of all excess 
deaths, respectively, providing clear focus for preventive 
interventions. These findings provide important informa-
tion for survivors, clinicians, and clinical guidelines, par-
ticularly in relation to preventing excess morbidity and 
mortality in survivors >60 years of age.
Figure 2. Absolute excess risk 
per 10 000 person-years for car-
diomyopathy/heart failure (CM/
HF) deaths for each calendar 
year of diagnosis.  
The curve was produced by fitting 
a restricted cubic spline with the 
number of CM/HF deaths per 1 
calendar year band as a weight. Point 
estimates of the absolute excess risk 
with corresponding 95% confidence 
intervals are plotted at the mean of 
the relevant treatment era (1940–
1969, 1970–1979, 1980–1989, and 
1990–2006). 
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Characteristic No. Dead % No. Alive % P-value Total No. % 
        
Overall 4475 13.0 30014 87.0  34489 100.0 
Sex         
Male 2629 13.9 16310 86.1  18939 100.0 
Female 1846 11.9 13704 88.1 <0.001 15550 100.0 
First Primary Neoplasm Type         
CNS (excluding PNET) 1334 19.1 5636 80.9  6970 100.0 
CNS PNET 340 28.4 858 71.6  1198 100.0 
Leukemia (excluding AML) 1104 11.6 8398 88.4  9493 100.0 
AML 82 8.4 899 91.6  981 100.0 
Hodgkin Lymphoma 331 14.8 1903 85.2  2234 100.0 
Non-Hodgkin Lymphoma 131 8.5 1418 91.5  1549 100.0 
Neuroblastoma 144 9.4 1391 90.6  1535 100.0 
Non-Heritable Retinoblastoma 31 3.1 975 96.9  1006 100.0 
Heritable Retinoblastoma 138 18.4 612 81.6  750 100.0 
Wilms 184 7.7 2204 92.3  1388 100.0 
Bone Sarcoma 198 16.6 997 83.4  1195 100.0 
Soft Tissue Sarcoma 253 11.8 1894 88.2  2147 100.0 
Other 205 6.7 2838 93.3 <0.001 3043 100.0 
Age at Diagnosis         
Mean 7.3  6.5   6.6  
0-4 1662 10.6 14035 89.4  15697 100.0 
5-9 1351 14.6 7913 85.4  9264 100.0 
10-14 1462 15.3 8066 84.7 <0.001 9528 100.0 
Treatment Era         
1940-1969 1329 35.5 2417 64.5  3746 100.0 
1970-1979 1247 23.2 4132 76.8  5379 100.0 
1980-1989 942 13.2 6205 86.8  7147 100.0 
1990-1999 703 7.0 9328 93.0  10031 100.0 
2000-2006 254 3.1 7932 96.9 <0.001 8186 100.0 
Years from Diagnosis              
Mean  17.0  23.9   23.0  
5-9 years 2054 37.9 3368 62.2  5422 100.0 
10-19 years 1060 9.1 10561 90.9  11621 100.0 
20-29 years 548 6.9 7352 93.1  7900 100.0 
30-39 years 417 7.7 5026 92.3  5443 100.0 
40-49 years 277 9.9 2529 90.1  2806 100.0 
50-59 years 103 8.9 1052 91.1  1155 100.0 
60+ years 16 11.3 126 88.7 <0.001 142 100.0 
Attained Age at Exit              
Mean  24.3  30.4   29.6  
5-9 years 416 48.9 435 51.1  851 100.0 
10-19 years 1831 21.7 6614 78.3  8445 100.0 
20-29 years 1003 9.4 9730 90.7  10733 100.0 
30-39 years 535 8.1 6083 91.9  6618 100.0 
40-49 years 364 7.5 4486 92.5  4850 100.0 
50-59 years 238 11.4 1859 88.7  2097 100.0 
60+ years 88 9.8 807 90.2 <0.001 895 100.0 
Supplemental Table I: Cohort characteristics of the British Childhood Cancer Survivor Study. 
Abbreviations: CNS – central nervous system, PNET – primitive neuroectodermal tumor, AML – acute myeloid leukemia  
  
Characteristic Treatment Era 
 1940-1969 
N 
1970-1979 1980-1989 1990-2006 
 N % N % N % N % 
         
Overall 3746 10.9 5379 15.6 7147 20.7 18217 52.8 
Sex         
Male 2019 53.9 2963 55.1 3941 55.1 10016 55.0 
Female 1727 46.1 2416 44.9 3206 44.9 8201 45.0 
First Primary Neoplasm Type         
CNS (excluding PNET) 1059 28.3 1094 20.3 1185 16.6 3632 19.9 
CNS PNET 167 4.5 174 3.2 236 3.3 621 3.4 
Leukemia (excluding AML) 168 4.5 1554 28.9 2206 30.9 5565 30.6 
AML 10 0.3 68 1.3 193 2.7 710 3.9 
Hodgkin Lymphoma 297 7.9 456 8.5 495 6.9 986 5.4 
Non-Hodgkin Lymphoma 179 4.8 206 3.8 403 5.6 761 4.2 
Neuroblastoma 217 5.8 153 2.8 307 4.3 858 4.7 
Non-Heritable Retinoblastoma 255 6.8 195 3.6 160 2.2 396 2.2 
Heritable Retinoblastoma 269 7.2 128 2.4 127 1.8 226 1.2 
Wilms 324 8.7 480 8.9 515 7.2 1069 5.9 
Bone Sarcoma 154 4.1 179 3.3 267 3.7 595 3.3 
Soft Tissue Sarcoma 310 8.3 302 5.6 453 6.3 1082 5.9 
Other 337 9.0 390 7.3 600 8.4 1716 9.4 
Age at Diagnosis         
0-4 1727 46.1 2326 43.2 3317 46.4 8327 45.7 
5-9 931 24.9 1567 29.1 1864 26.1 4902 26.9 
10-14 1088 29.0 1486 27.6 1966 27.5 4988 27.4 
Years from Diagnosis         
Mean  41.3  33.3  26.7  14.7  
5-9 458 12.2 524 9.7 459 6.4 3981 21.9 
10-19 214 5.7 319 5.9 338 4.7 10750 59.0 
20-29 166 4.4 243 4.5 4005 56.0 3486 19,1 
30-39 202 5.4 2896 53.8 2345 32.8 0 0 
40-49 1409 37.6 1397 26.0 0 0 0 0 
50-59  1155 30.8 0 0 0 0 0 0 
60+ 142 3.8 0 0 0 0 0 0 
Attained Age at Exit         
Mean  47.8  40.0  33.3  21.3  
5-9 86 2.3 105 2.0 95 1.3 565 3.1 
10-19 405 10.8 478 8.9 429 6.0 7133 39,2 
20-29 219 5.9 314 5.8 1474 20.6 8726 47.9 
30-39 193 5.2 902 16.8 3730 52.2 1793 9,8 
40-49 605 16.2 2826 52.5 1419 19.9 0 0 
50-59  1343 35.9 754 14.0 0 0 0 0 
60+ 895 23.9 0 0 0 0 0 0 
Supplemental Table II: Cohort characteristics of the British Childhood Cancer Survivor Study by treatment era. 
Abbreviations: CNS – central nervous system, PNET – primitive neuroectodermal tumor, AML – acute myeloid leukemia  
 First Primary Neoplasm Type 
Attained Age (years) 
5-9 10-19 20-29 30-39 40-49 50-59 60+ 
N % N % N % N % N % N % N % 
CNS (excluding PNET) 159 18.7 1553 18.4 2258 21.0 1196 18.1 977 20.1 559 26.7 268 29.9 
CNS PNET 19 2.2 371 4.4 381 3.6 193 2.9 148 3.1 62 3.0 24 2.3 
Leukemia (excluding AML) 285 33.5 2987 35.4 3092 28.8 1892 28.6 1102 22.7 126 6.0 9 1.0 
AML 36 4.2 320 3.8 363 3.4 181 2.7 58 1.2 22 1.1 1 0.1 
Hodgkin Lymphoma 3 0.4 248  2.9 705 6.6 471 7.1 497 10.3 228 10.9 82 9.2 
Non-Hodgkin Lymphoma 14 1.7 217 2.6 457 4.3 417 6.3 255 5.3 123 5.9 66 7.4 
Neuroblastoma 100 11.8 550 6.5 412 3.8 225 3.4 135 2.8 95 4.5 18 2.0 
Non-Heritable Retinoblastoma 31 3.6 214 2.5 230 2.1 154 2.3 201 4.1 122 5.8 54 6.0 
Heritable Retinoblastoma 51 6.0 151 1.8 148 1.4 127 1.9 142 2.9 97 4.6 34 3.8 
Wilms 48 5.6 624 7.4 627 5.8 488 7.4 405 8.4 155 7.4 41 4.6 
Bone Sarcoma 4 0.5 182 2.2 365 3.4 270 4.1 203 4.2 100 4.8 71 7.9 
Soft Tissue Sarcoma 35 4.1 454 5.4 676 6.3 409 6.2 306 6.3 173 8.3 94 10.5 
Other 66 7.8 574 6.8 1019 9.5 595 9.0 421 8.7 235 11.2 133 14.9 
Supplemental Table III: First primary neoplasm diagnoses of the British Childhood Cancer Survivor Study by attained age. 
Abbreviations: CNS – central nervous system, PNET – primitive neuroectodermal tumor, AML – acute myeloid leukemia  
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 Overall Cardiac Mortality Ischemic Heart Disease Mortality Cardiomyopathy/Heart Failure Mortality 
 
RR (95%CI) EMR (95%CI) RR (95%CI) EMR (95%CI) RR (95%CI) EMR (95%CI) 
Sex 
      Male 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Female 2.2 (1.6,3.0) 1.1 (0.7,1.6) 1.9 (1.2,3.0) 0.7 (0.4,1.3) 3.0 (1.7,5.2) 1.5 (0.8,2.9) 
Pheterogeneity <0.0001 0.7771 0.0091 0.2600 0.0002 0.2179 
First Primary Neoplasm Type       
CNS (excluding PNET) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
CNS PNET 1.2 (0.5,3.2) 0.9 (0.2,5.4) 1.9 (0.6,5.5) 1.7 (0.3,12.5) 1.7 (0.2,15.0) 3.8 (0.2,61.0) 
Leukemia (excluding AML) 0.7 (0.4,1.4) 0.8 (0.3,1.8) 0.4 (0.1,1.5) 0.2 (0.0,4.4) 1.7 (0.5,5.4) 3.2 (0.4,23.6) 
AML 5.8 (2.8,12.1) 7.6 (3.2,18.1) 1.7 (0.2,12.6) 2.3 (0.2,23.5) 19.2 (5.7,64.8) 39.8 (5.5,289.6) 
Hodgkin Lymphoma 2.7 (1.6,4.4) 4.0 (1.9,8.2) 2.4 (1.3,4.5) 3.6 (1.3,9.8) 3.8 (1.0,13.6) 4.9 (0.5,45.8) 
Non-Hodgkin Lymphoma 2.0 (1.1,3.6) 3.0 (1.4,6.6) 1.4 (0.6,3.3) 2.1 (0.6,7.1) 5.4 (1.5,19.2) 13.8 (1.8,106.1) 
Neuroblastoma 0.7 (0.2,2.1) 0.8 (0.2,3.0) 0.4 (0.1,3.2) 0.5 (0.0,9.1) 1.2 (0.1,10.7) 2.2 (0.1,38.4) 
Non-Heritable Retinoblastoma 0.2 (0.1,1.0) 0.1 (0.0,3.2) 0.5 (0.1,2.1) 0.5 (0.0,5.0) NE NE 
Heritable Retinoblastoma 0.7 (0.2,2.0) 0.4 (0.0,4.7) 1.4 (0.4,4.5) 1.5 (0.2,9.9) NE NE 
Wilms 1.7 (0.9,3.1) 1.9 (0.8,4.3) 2.2 (1.0,5.1) 2.8 (0.8,9.5) 2.5 (0.7,9.9) 5.0 (0.6,41.7) 
Bone Sarcoma 1.4 (0.6,2.9) 1.6 (0.5,4.9) 1.1 (0.4,3.0) 0.9 (0.1,8.6) 2.6 (0.5,14.2) 6.2 (0.5,71.1) 
Soft Tissue Sarcoma 1.1 (0.5,2.1) 1.0 (0.3,2.9) 1.0 (0.4,2.4) 0.9 (0.2,4.5) 3.5 (0.9,13.2) 8.0 (1.0,65.0) 
Other 1.1 (0.6,2.1) 1.0 (0.4,2.8) 1.2 (0.6,2.6) 1.2 (0.3,4.6) 2.1 (0.5,8.3) 3.6 (0.4,36.0) 
Pheterogeneity <0.0001 <0.0001 0.0412 0.0760 0.0003 0.0002 
Age at Diagnosis       
0-4 years 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
5-9 years 0.7 (0.5,1.1) 0.7 (0.4,1.2) 0.9 (0.5,1.8) 1.0 (0.4,2.8) 0.7 (0.3,1.4) 0.7 (0.3,1.6) 
10-14 years 0.5 (0.4,0.8) 0.5 (0.3,0.9) 0.8 (0.4,1.6) 1.0 (0.3,2.7) 0.5 (0.2,1.1) 0.5 (0.2,1.2) 
Ptrend 0.0078 0.0211 0.5110 0.8914 0.0666 0.0986 
Treatment Era       
<1970 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
1970-1979 1.6 (1.0,2.5) 1.3 (0.7,2.4) 1.5 (0.9,2.6) 1.0 (0.4,2.2) 8.9 (2.1,37.8) 13.9 (1.1,168.5) 
1980-1989 2.3 (1.4,3.9) 1.8 (0.9,3.5) 0.8 (0.3,2.0) 0.3 (0.1,1.4) 18.2 (3.9,84.2) 28.9 (2.4,354.6) 
1990-2006 1.0 (0.4,2.1) 0.6 (0.2,1.5) 1.0 (0.3,3.8) 0.4 (0.1,2.0) 3.7 (0.6,23.3) 4.5 (0.3,69.4) 
Ptrend 0.1318 0.8583 0.9171 0.1098 0.1231 0.3453 
Pquadratic 0.0014 0.0072 0.2518 0.6850 <0.0001 <0.0001 
Attained Age       
5-19 years 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
20-29 years 0.8 (0.5,1.5) 1.9 (1.0,3.7) 1.3 (0.2,10.0) 11.4 (1.3,102.2) 0.9 (0.4,2.0) 1.6 (0.7,3.6) 
30-39 years 0.6 (0.3,1.0) 3.6 (1.8,7.2) 0.4 (0.0,3.1) 19.8 (2.2,182.6) 1.0 (0.4,2.3) 2.9 (1.2,7.2) 
40-49 years 0.3 (0.2,0.7) 5.7 (2.5,13.0) 0.2 (0.0,1.8) 30.1 (3.0,298.5) 0.4 (0.1,1.4) NE 
50-59 years 0.4 (0.2,0.8) 17.1 (6.6,44.7) 0.2 (0.0,2.0) 93.2 (9.1,949.8) 2.2 (0.5,10.4) 21.3 (3.1,147.8) 
60+ years 0.4 (0.2,1.0) 45.7 (14.5,144.1) 0.3 (0.0,2.6) 267.5 (23.9,2992.9) 2.0 (0.1,26.7) NE 
Ptrend 0.0065 <0.0001 0.0344 <0.0001 0.8121 0.0591 
Supplemental Table V: Relative risks and excess mortality ratios per 10,000 person-years estimated using a multivariable model, adjusting for sex, first primary neoplasm type, 
age at diagnosis, treatment era, and attained age. 
Abbreviations: CNS – central nervous system, PNET – primitive neuroectodermal tumor, AML – acute myeloid leukemia, RR – relative risks, EMR – excess mortality ratios, CI – 
confidence intervals, NE – not estimable 
 Overall Cardiac Mortality 
 
RR (95%CI) EMR (95%CI) 
Sex 
  Male 1 (ref) 1 (ref) 
Female 2.4 (1.6,3.7) 1.1 (0.7,1.9) 
Pheterogeneity <0.0001 0.5805 
First Primary Neoplasm Diagnosis   
CNS (excluding PNET) 1 (ref) 1 (ref) 
CNS PNET 0.4 (0.1,2.9) 0.4 (0.0,6.6) 
Leukemia (excluding AML) 0.6 (0.3,1.2) 0.7 (0.3,1.7) 
AML 4.9 (2.2,11.1) 6.7 (2.5,17.9) 
Hodgkin Lymphoma 2.2 (1.1,4.4) 3.3 (1.3,8.3) 
Non-Hodgkin Lymphoma 2.0 (0.9,4.5) 3.1 (1.2,8.4) 
Neuroblastoma 0.3 (0.0,2.4) 0.4 (0.0,3.6) 
Non-Heritable Retinoblastoma 0.3 (0.0,2.6) 0.4 (0.0,4.7) 
Heritable Retinoblastoma NA NA 
Wilms 1.2 (0.5,2.7) 1.4 (0.5,3.9) 
Bone Sarcoma 1.8 (0.7,4.6) 2.5 (0.7,8.4) 
Soft Tissue Sarcoma 1.2 (0.5,3.0) 1.6 (0.5,4.8) 
Other 0.8 (0.3,2.0) 0.7 (0.2,2.9) 
Pheterogeneity 0.0002 0.0001 
Age at Diagnosis   
0-4 years 1 (ref) 1 (ref) 
5-9 years 0.6 (0.4,1.1) 0.7 (0.4,1.2) 
10-14 years 0.5 (0.3,0.9) 0.5 (0.2,0.9) 
Ptrend 0.0216 0.0312 
Treatment Era   
1970-1974 1 (ref) 1 (ref) 
1975-1979 1.6 (0.9,2.9) 1.8 (0.8,4.2) 
1980-1984 1.9 (1.0,3.5) 2.1 (0.9,4.8) 
1985-1989 1.8 (0.9,3.7) 1.9 (0.7,4.6) 
1990-1994 0.9 (0.4,2.4) 0.8 (0.3,2.7) 
1995-1999 0.6 (0.2,2.1) 0.4 (0.1,2.4) 
Ptrend 0.7687 0.3521 
Pquadratic 0.0024 0.0019 
Attained Age   
5-19 years 1 (ref) 1 (ref) 
20-29 years 0.8 (0.4,1.4) 1.8 (0.9,3.7) 
30-39 years 0.5 (0.2,0.9) 3.0 (1.4,6.3) 
40-49 years 0.3 (0.2,0.8) 4.9 (1.8,13.5) 
50+ years 0.3 (0.1,1.4) 15.8 (2.5,101.2) 
Ptrend 0.0068 0.0004 
Supplemental Table VI: Relative risks and excess mortality ratios per 10,000 person-years estimated using a multivariable model, 
adjusting for sex, first primary neoplasm type, age at diagnosis, treatment era, and attained age. For these analyses, the British 
Childhood Cancer Survivor Study was restricted to the diagnosis period to 1970-1999 in order to compare with the Childhood Cancer 
Survivor Study. 
Abbreviations: CNS – central nervous system, PNET – primitive neuroectodermal tumor, AML – acute myeloid leukemia, RR – 
relative risks, EMR – excess mortality ratios, CI – confidence interval, NA – not applicable 
  
 
 
Supplemental Figure I: Cumulative mortality of all cardiac causes, ischemic heart disease causes, and cardiomyopathy/heart failure causes among childhood cancer survivors 
compared to that expected in the general population, by follow-up (years since diagnosis). 
Abbreviations: CM/HF – cardiomyopathy/heart failure, IHD – ischemic heart disease  
